Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 11/20 | 0.62 |
| ▸ | NOS1 | P29475 | 10/20 | 0.62 |
| ▸ | NOS3 | P29474 | 7/20 | 0.62 |
| ▸ | CCR1 | P32246 | 1/20 | 0.55 |
| ▸ | CCR5 | P51681 | 1/20 | 0.55 |
| ▸ | CCR8 | P51685 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDE8A | O60658 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30240847 | 1.00 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL15221096 | 0.82 | NOS2 (0.61) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL2760431 | 0.82 | NOS2 (0.65) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL29694712 | 0.80 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL3307860 | 0.80 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL7674585 | 0.80 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL1061501 | 0.80 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL30164187 | 0.80 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL18291870 | 0.80 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL245100 | 0.80 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-110914280-B | 6H-thieno [2,3-e ] [1,2,4] triazolo [3,4-c ] [1,2,4] triazab derivatives | 阿尤米制药公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-05-06 | — | — | US | disclosed |
| EP-3640253-A1 | 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI Pharmaceutical Corporation (JP) | 2020-04-22 | — | — | EP | disclosed |
| CN-110914280-A | 6H-thieno [2,3-e ] [1,2,4] triazolo [3,4-c ] [1,2,4] triaza derivatives | 阿尤米制药公司 | 2020-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | BRD4, BRD3, BRD2 | NOS2 4178/4885NOS1 3969/4885NOS3 3534/4885 |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | BRD4, BRD3, BRD2 | NOS2 4178/4885NOS1 3969/4885NOS3 3534/4885 |
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | PNPO, PDXK, PLPBP | NOS2 3147/4885NOS1 2407/4885NOS3 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.